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Prevention Conference VI
Diabetes and Cardiovascular Disease
Writing Group III: Risk Assessment in Persons With Diabetes
Rita F. Redberg, MD, MSc, Chair; Philip Greenland, MD, Co-Chair; Valentin Fuster, MD, PhD;
Kalevi Pyörälä, MD; Steven N. Blair, PED; Aaron R. Folsom, MD; Anne B. Newman, MD;
Daniel H. O’Leary, MD; Trevor J. Orchard, MD, MBBCh, MMedSci; Bruce Psaty, MD, PhD;
J. Sanford Schwartz, MD; Rodman Starke, MD; Peter W.F. Wilson, MD
This Writing Group addressed whether the high riskassociated with diabetes can be averted by detection of
subclinical or early cardiovascular disease (CVD) that would
enable earlier focused intervention. This article will discuss
current data and recommendations for risk assessment of
CVD in persons with diabetes.
Screening Principles
Screening aims at accurately and cost-effectively identifying
disease (or risk of disease development) in persons without
outward manifestations of the disease. A critical underlying
assumption of screening is that test results will lead to a
change in clinical management that can decrease morbidity
and mortality. Because of the recognized high risk for
cardiovascular events in patients with diabetes, the American
Heart Association (AHA) currently recommends that they
belong in the same high-risk category previously reserved for
patients with known CVD.1 The recently released third report
of the National Cholesterol Education Program on detection,
evaluation, and treatment of high blood cholesterol in adults
is consistent with the AHA guidelines.2 The updated recom-
mendations from the Adult Treatment Panel III place patients
with diabetes in a category of coronary heart disease (CHD)
risk equivalents in which risk equates to that of persons with
established CHD. For Adult Treatment Panel III, recommen-
dations for lipid-lowering therapy are the same for CHD risk
equivalents and established CHD. If this principle is extended
to modification of other risk factors (ie, risk factors in
asymptomatic persons with diabetes are treated in the same
manner as those for people with established CVD), noninva-
sive testing for risk stratification among patients with diabe-
tes would do little to change clinical management of risk
factors. Specifically, if a patient with diabetes were to
undergo screening and results were found to be negative for
subclinical CVD, the patient still would be regarded as high
risk on the basis of diabetes alone and should receive
aggressive risk factor modification. Conversely, if a screen-
ing test were positive for subclinical CVD, this result would
also not change recommended management, because the
patient is already considered to be at high risk for cardiovas-
cular events. Therefore, again, intensive risk factor identifi-
cation and intervention would be justified. There are no data
showing benefit of treating asymptomatic persons with anti-
ischemic medications or revascularization, so risk stratifica-
tion cannot be recommended on the basis of evidence of
benefit of further treatment in this group. However, a current
trial (BARI 20) will examine the benefit of early revascular-
ization in persons with diabetes who show evidence of
cardiac ischemia, irrespective of symptomatology.
Current Clinical Practice Guidelines for
Noninvasive Testing in Persons With Diabetes
Several guidelines in this category will be reviewed.
French Guideline
A French Guideline for Detection of Silent Myocardial
Ischemia in persons with diabetes was published in 1995.
This guideline recommends screening for silent myocardial
ischemia by exercise stress test or thallium stress in persons
with diabetes who have peripheral arterial disease (PAD),
proteinuria, or major CVD risk factors or who are over 65
years of age. Goals of early detection of CVD are not clearly
defined in this guideline, and this limitation is seen in the
other available guidelines as well.3
American College of Cardiology/AHA
The American College of Cardiology (ACC)/AHA published
guidelines for exercise testing in 1997. Exercise treadmill
testing in persons with diabetes was given a data quality
rating of IIb (usefulness or efficacy less well established by
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evidence or opinion); the guideline also stated that exercise
treadmill testing in general “might be useful in people with
heightened pretest risk.”4
American Diabetes Association/ACC
The most recent guideline was the American Diabetes Asso-
ciation (ADA)/ACC Consensus Statement on Diabetes and
Cardiovascular Disease published in 1998.5 This guideline
recommends noninvasive cardiac testing of asymptomatic
persons with diabetes who have PAD or cerebrovascular
disease, those with major or minor electrocardiographic
(ECG) changes at rest, or those with 2 CVD risk factors.
Various tests were suggested as possible modalities for
screening: thallium stress test, stress echocardiogram, or
stress ECG. The authors of the guideline stated that in the
absence of data, these recommendations were made on the
basis of “clinical judgment and subgroup analysis of data
from nondiabetic populations.”
The goals of early detection are not clearly defined in any
of the 3 currently available guidelines. In fact, there are few
data on which to base clinical practice recommendations for
this type of testing in asymptomatic persons with diabetes.
Conclusion
In the absence of any clinical trial data to suggest a benefit of
stress testing for myocardial ischemic disease in asymptom-
atic persons with diabetes, routine use of these tests cannot be
recommended.
Office-Based Risk Factor Assessment
Office-based risk factor assessment has the advantage of
being the best-studied method for CVD risk prediction and
also of identifying specific risk factors that require interven-
tion (see Table 1 from the Writing Group I report6). Thus, it
is the reference standard for determining CVD risk. The
largest body of data comes from the Framingham Heart
Study, a landmark epidemiological study of cardiovascular
risk factors that began in the late 1940s. The Framingham risk
score, which can be easily calculated by office-based assess-
ment of CVD risk factors, has been validated in other
population-based samples over the past 2 decades.7 It allows
calculation of future risk of cardiac events and allows easy
identification of risk factors for modification. The risk based
on Framingham score for several different representative
persons with diabetes varies by age, sex, and risk factors, but
is always 40% higher in persons with diabetes8 (Table 1
from the Writing Group I report). The Framingham score
calculator can be downloaded for use on a PalmPilot from
www.statcoder.com. It should be recognized that many per-
sons with diabetes have high absolute risk, and therefore,
AHA recommendations are to treat them in the same risk
category as if they had CVD. Thus, individual absolute risk
assessment may not be needed. However, certain groups (eg,
young women with diabetes) may be at lower 10-year CVD
risk, and the decision to treat may warrant thought and
consideration of future risk and benefit over a lifetime.
The United Kingdom Prospective Diabetes Study (UK-
PDS) also provides data for calculation of risk in persons with
diabetes, and the values obtained with this database can be
compared with the Framingham data. The UKPDS risk
engine is being developed and will also allow calculation of
CVD risk for persons with diabetes.
There are several new markers being evaluated for predic-
tion of cardiovascular risk. Blood markers of inflammation
(low albumin and elevated fibrinogen, von Willebrand factor,
or white blood cell count) have been shown to be indepen-
dently, albeit weakly, associated with risk of CVD in persons
with type 2 diabetes.9 In the Atherosclerosis Risk In Com-
munities (ARIC) study,9 the following nontraditional blood
risk factors were not independently associated with risk of
CVD in persons with diabetes: high-density lipoprotein sub-
fractions, apolipoproteins A1 and B, lipoprotein(a), creati-
nine, and factor VII. C-reactive protein has been shown to
have predictive value in nondiabetic populations10 but has not
been well studied in persons with diabetes.
Conclusion
It is not clear that any of these biochemical assessments add
significantly to risk prediction models over traditional risk
factor assessment. Therefore, they are not recommended for
use in persons with diabetes.
Lifestyle Assessments
Diet
Dietary assessment is crucial for prevention of diabetes and
management of persons with diabetes. The most common
form of diabetes, type 2, is associated with a metabolic
syndrome characterized by central obesity and insulin resis-
tance. The increase in CVD risk associated with diabetes can
be ameliorated by controlling the individual risk factors.11
Reducing caloric intake and increasing physical activity to
achieve even a modest weight loss can improve insulin
resistance and the associated metabolic abnormalities. The
risk of microvascular complications of diabetes is greatly
reduced by improving glycemic control, although there is less
evidence showing a reduction in risk for macrovascular
disease.12,13 There is recent evidence that dietary cholesterol
intake is particularly strongly associated with CHD risk in
patients with diabetes.14
Physical Activity
Physical inactivity or a low level of cardiorespiratory fitness
(CRF) is an independent risk factor for CVD.15 Most of the
data on sedentary habits and mortality have been obtained
from studies of apparently healthy women and men.16 Be-
cause other CVD risk factors appear to have similar effects in
nondiabetic and diabetic populations, it is reasonable to
assume that inactivity or low CRF may also be hazardous for
patients with type 2 diabetes. Data on inactivity or low CRF
as a predictor of mortality in men with type 2 diabetes have
recently supported this assumption.17 Wei et al17 performed
follow-up on a cohort of 1263 men for an average of 11.7
years after a clinical examination that included a maximal
exercise test. There were 180 deaths (92 of CVD) during
14 777 person-years of observation. Men reporting no phys-
ical activity in the 3 months before the examination were
classified as inactive. Inactive men were 1.8 times more
likely than active men to die during follow-up (adjusted for
2 Circulation May 7, 2002
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age and examination year). Unfit men were those with low
exercise test tolerance, defined by maximal metabolic equiv-
alents (multiples of resting metabolic rate) attained on the
test. Unfit men had significantly higher risk for all-cause
mortality in high- and low-risk strata of other mortality
predictors.
Conclusion
Lifestyle assessment should be undertaken so that appropriate
risk reduction measures can be initiated.
Exercise Testing
Assessment of CRF
Exercise testing can be used for several purposes. The
traditional ECG-monitored exercise test is used for diagnosis
of CVD, and an abnormal test can be predictive of future
major coronary events. Exercise testing also can be used to
evaluate CRF. CRF has a strong, independent, and inverse
association with risk of CVD and all-cause mortality. CRF
can be determined by the traditional ECG-monitored exercise
test, but it also can be assessed more simply and inexpen-
sively with nonmedically monitored, submaximal exercise
tests. Typical approaches to fitness testing involve use of a
cycle ergometer or treadmill. Most protocols include at least
2 exercise stages, which often are selected to produce
exercise heart rates of 50% and 70% of age-predicted
maximal heart rates.18 These tests can be administered by
nurses, physical therapists, or exercise physiologists in primary
care settings and also are available in most communities at
health clubs and other exercise facilities. The cost of a submaxi-
mal fitness test is modest, often in the range of $25 to $50.
Exercise ECG Testing
Exercise testing has been used in numerous studies of persons
with diabetes, but the reports are mostly small case series, and
it is difficult in many instances to judge study quality. Typical
anginal symptoms may not be a reliable way to screen for
ischemia in persons with diabetes, because angina does not
reliably accompany exercise-induced ischemia.19 Callaham et
al20 showed in a large series of US veterans with diabetes that
exercise-induced ST-segment depression was associated with
more CVD events on follow-up, and ECG ischemia, with or
without associated angina, conferred a worse prognosis for
development of CVD. Data from the Coronary Artery Sur-
gery Study registry showed that patients with diabetes with
silent myocardial ischemia had worse outcome in terms of
CVD events than persons without diabetes with silent myo-
cardial ischemia.21
Conclusions
Although symptoms may be less reliable for detection of
ischemic heart disease in persons with diabetes, ischemic
exercise ECG findings appear to be at least as predictive of
prognosis, and possibly indicative of even worse outcome,
when diabetes is present as in persons without diabetes.
However, there are no outcome data available to show benefit
of early identification of asymptomatic CVD in patients with
diabetes.
Exercise Echocardiographic Testing
Exercise echocardiographic testing has been shown to pro-
vide incremental prognostic information in the general pop-
ulation. Few studies have focused specifically on persons
with diabetes. In a study of the long-term prognostic value of
a negative, nonischemic stress echocardiogram in patients
with and without diabetes, 236 consecutive subjects (89
diabetic patients) who had stress echocardiography and who
tested negative for inducible ischemia were followed up for a
mean of 25 months.22 Diabetic patients had a significantly
higher incidence of cardiac events (19% versus 9.7%,
P0.03) and worse event-free survival (P0.03) than pa-
tients without diabetes. There were more nonfatal myocardial
infarctions in the diabetic group (6.7% versus 1.4%, P0.05)
and a trend toward a higher proportion of hard events
(myocardial infarction and cardiac death) in diabetic patients
(12.4% versus 5.6%, P0.11). The rate of hard events
annually was 2.7% in nondiabetic and 6.0% in diabetic
patients. Compared with nondiabetic patients, patients with
diabetes who have negative stress echocardiograms appear to
remain at greater risk for cardiac events, possibly because of
a higher prevalence of established coronary disease in pa-
tients with diabetes.
Conclusions
On the basis of limited data, it appears that exercise echocar-
diography offers prognostic information in patients with
diabetes, but even with negative studies, patients with diabe-
tes are at higher risk for cardiac events than patients without
diabetes. There are no outcome data available that show a
benefit of testing in the asymptomatic population, and thus,
routine use of this test cannot be recommended.
Nuclear Perfusion Imaging
Nuclear perfusion imaging (single photon emission computed
tomography [SPECT]) has been shown to provide incremen-
tal prognostic information in the general population. Few
studies have specifically focused on persons with diabetes.
Kang et al23 assessed 1271 consecutive persons with diabetes
and 5862 persons without diabetes from a coronary angiog-
raphy population with known or suspected CVD. Most
patients were symptomatic and were not reported separately
from asymptomatic patients. Over the 2-year follow-up pe-
riod, patients with diabetes had significantly higher rates of
hard events (cardiac death or nonfatal myocardial infarction;
4.3% versus 2.3% per year, P0.001) and higher total event
rates (hard events and late revascularization). These investi-
gators concluded that in mostly symptomatic patients, both
normal and abnormal SPECT results were predictive of
significant clinical outcomes in patients with and without
diabetes. In this symptomatic population, abnormal scans
were common both in patients with diabetes and in those
without diabetes and predicted poor outcomes, whereas
normal scans predicted near-normal outcomes in both groups.
In a study of 925 asymptomatic subjects with type 2
diabetes, exercise ECG was performed in all patients, and
thallium scan was also used if the exercise ECG was
abnormal or equivocal.24 In the 59 patients with diabetes who
had an abnormal resting ECG, 25% (15) had an abnormal
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thallium scan, whereas in the 866 persons with diabetes who
had a normal resting ECG, only 5% (44) had an abnormal
thallium scan. Overall, 6% of this population (59 of 925) had
an abnormal thallium scan; however, because normal ECGs
are much more common than abnormal ECGs, most abnormal
scans occurred in patients with normal resting ECGs. This
study did not confirm that abnormal exercise tests were
associated with significant coronary stenosis or cardiac
events.
In a recent study of noninvasive risk stratification, 4755
patients with symptoms of CHD, 929 of whom were diabetic,
who were undergoing stress myocardial perfusion imaging
were prospectively followed up (2.51.5 years) for the
subsequent occurrence of cardiac death, myocardial infarc-
tion, and revascularization. Patients with diabetes, despite an
increased revascularization rate, had 80 cardiac events (8.6%;
39 deaths and 41 myocardial infarctions) compared with 172
cardiac events (4.5%; 69 deaths and 103 myocardial infarc-
tions) in the nondiabetic cohort (P0.0001). Diabetic women
had the worst outcome for any given extent of myocardial
ischemia. Thus, as seen for exercise echocardiography, com-
pared with nondiabetic patients, diabetic patients with nega-
tive stress perfusion scans are at greater risk for cardiac
events than patients without diabetes.25,26
Conclusions
On the basis of relatively limited information, it appears that
exercise SPECT imaging results can be useful in assessing
prognosis. As in nondiabetic cohorts, pretest probability has
been confirmed in persons with diabetes as a predictor of
subsequent test results. If any noninvasive study is done in
low-probability patients, most studies will be negative. A
resting ECG abnormality and the presence of CVD risk
factors identify higher pretest probability. There are no
outcome data available showing a benefit of testing in an
asymptomatic population, and thus, the routine use of this test
cannot be recommended.
Measures of Subclinical Vascular Disease
These include a variety of tests to determine the presence of
asymptomatic atherosclerosis in various vascular beds. This
testing is based on the principle that atherosclerosis is a
systemic disease of the arterial tree, with preferential involve-
ment of the aorta and its large branches, coronary arteries,
cerebral arteries, and lower-extremity arteries. Pathological
studies have documented that the extent of atherosclerosis in
all these arterial sites is greater in middle-aged or elderly
subjects with diabetes, most of whom have type 2 diabetes,
than in nondiabetic subjects of the same age27–29; to some
extent, this difference appears to diminish with age.28 Mor-
tality and morbidity caused by CHD and cerebrovascular
disease are the most frequent clinical manifestations of
atherosclerotic disease in both subjects with and without
diabetes; nonetheless, lower-extremity PAD also leads to
substantial morbidity and disability, particularly among the
elderly. The risk of all these forms of atherosclerotic disease
is markedly higher in patients with diabetes than in nondia-
betic subjects.
Patients with atherosclerotic disease in one arterial site are
likely to have advanced atherosclerosis in other large arteries
as well. Pathological studies have revealed correlation be-
tween the extent of atherosclerotic involvement in different
arterial sites,30–32 although these correlations apply imper-
fectly to individuals. These observations have focused atten-
tion on noninvasive methods for the detection of subclinical
atherosclerosis in those arterial sites that are easily accessible
for a noninvasive evaluation, namely, lower-extremity arter-
ies and carotid arteries. The underlying hope is that subclin-
ical atherosclerosis in these arterial beds could be used as a
marker of a generalized atherosclerotic burden and as a
predictor of an increased risk of clinical CVD arising from the
less-accessible arterial sites, particularly coronary arteries and
cerebral arteries. The recent AHA Prevention Conference V33
addressed the utility of noninvasive tests of atherosclerotic
burden for identification of high-risk individuals among
asymptomatic subjects in the general population.
Ankle-Brachial Blood Pressure Index
The ankle-brachial blood pressure index (ABI) has proved to
be a useful test for detecting subclinical PAD. This test is
simple and inexpensive and can be done in a physician’s
office. If operators are well trained, reliability is good, and the
validity for detection of 50% stenosis in lower-extremity
arteries is high.34 The equipment needed consists of an
ordinary blood pressure cuff and a Doppler ultrasonic sensor.
With a standardized protocol,35 systolic blood pressure is
measured in both arms and at the left and right posterior tibial
arteries and dorsalis pedis arteries. The ABI is calculated for
each leg as a ratio of the higher of the 2 ankle systolic blood
pressures (posterior tibial or dorsalis pedis) to the average of
the right and left brachial artery systolic pressures. In case the
right and left arm pressure difference is 10 mm Hg, the
higher pressure is used. An ABI0.90 for either leg has been
given as a threshold value indicating the presence of PAD.
Lower ABI values indicate more severe stenosing lesions.
Determination of ABI is compromised by noncompress-
ibility of the ankle arteries caused by medial arterial calcifi-
cation (Mönckeberg’s sclerosis), which may occur in elderly
nondiabetic subjects but is more common in subjects with
diabetes. In such instances, the indirectly measured systolic
ankle pressure is 300 mm Hg or 75 mm Hg above arm
pressure. In this context, it is important to note that medial
arterial calcification has been shown to be an independent
predictor of the risk of CVD death in patients with type 2
diabetes.36–38 The effect of medial arterial calcification on
utility of ABI in persons with diabetes merits further study.
Population-based studies have demonstrated the relation-
ship of a low ABI with prevalent clinically manifest CVD
arising from other arterial territories39 and the predictive
value of a low ABI with regard to future all-cause mortality
and CVD mortality and the risk of nonfatal CVD events.40–45
In a 10-year follow-up study of the Rancho Bernardo popu-
lation of men and women with a mean age of 66 years, Criqui
et al40 found that when subjects with baseline CVD were
excluded and adjustment was made for cardiovascular risk
factors, the relative risk of dying among subjects with
ABI-detected PAD was increased. Among men without
4 Circulation May 7, 2002
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baseline CVD, the 10-year CVD mortality rate was 33.8%
among those with subclinical PAD but only 5.6% among
those without it. Among women, the corresponding mortality
rates were 15.4% and 2.9%. The prevalence of a low ABI is
strongly age dependent; low ABI values have been found to
become more frequent in subjects older than 50 years.46 The
findings from the Cardiovascular Health Study appear to
indicate that in the absence of clinically manifest CVD, the
increase in the risk of CVD death associated with a low ABI
would be similar in diabetic and nondiabetic subjects.1
ABI testing could also be used to screen for PAD in the
hope of preventing amputation as a CVD outcome, particu-
larly in high-risk patients such as persons with diabetes.
Because the preventive medical treatment is the same for
PAD as for CVD, early diagnosis may not change medical
management. However, it is important to bear in mind the
significant morbidity that occurs from PAD in patients with
diabetes, and aggressive risk factor modification may prevent
this complication as well. However, evidence of the benefit of
ABI screening in this setting has not been demonstrated yet.
Conclusions
There is convincing evidence from population-based studies
that the ABI is a useful noninvasive measure for the detection
of subclinical PAD and that a low ABI may provide incre-
mental information beyond that provided by cardiovascular
risk factor measurements, “especially in people aged 50 years
and older or those who appear to be at intermediate or higher
risk for CVD on the basis of traditional risk factor assess-
ment, such as cigarette smokers or individuals with diabe-
tes.”1 Population-based studies have demonstrated that the
prevalence of PAD, both clinically established and subclini-
cal, is higher among subjects with diabetes than among
nondiabetic subjects of the same age and sex. Thus far,
studies applying ABI for the detection of subclinical PAD
have included too few subjects with diabetes to allow reliable
estimations of the contribution of this noninvasive test to the
prediction of the future risk of CVD mortality and morbidity
among asymptomatic subjects with diabetes.
B-Mode Ultrasound Measurement of Carotid
Intima-Media Thickness
B-mode ultrasound can visualize noninvasively the lumen
and walls of carotid arteries, aorta, and femoral arteries.
Current methods for the measurement of intima-media thick-
ness (IMT) are based on that described by Pignoli et al.47
Protocols used in different studies, however, have not been
uniform, and therefore, the reliability of the method has been
evaluated separately in each study.48 The examination is
performed bilaterally on the extracranial carotid artery seg-
ments: the distal straight 1 cm of the common carotid arteries,
the carotid bifurcations, and the proximal 1 cm of the internal
carotid arteries. Some studies conducted measurements on
both near and far walls of each segment, whereas other
studies performed measurements only on far walls, and in yet
other studies, measurements were limited to the common
carotid artery. Studies also differed in the method of selection
of sites for the measurements made on the frozen ultrasound
images from videotapes on each carotid artery segment. From
measurements on both sides, mean values can be calculated
for each carotid segment and for combined segments. When
one interprets results using carotid IMT as a measure of
subclinical atherosclerosis, it must be understood that IMT
does not directly measure the degree of stenosing atheroscle-
rosis. Pathological studies, however, demonstrate that in the
early phases of atherosclerosis, both intimal and medial layers
of the arterial wall become involved.
Population-based studies reveal that increased common
carotid artery IMT is associated with prevalent CVD49–52;
moreover, carotid IMT measurements carry predictive value
for future risk of CVD events and stroke.53–56 In the ARIC
study, the hazard ratio for CVD risk for IMT 1 mm versus
1 mm was 5.07 in women (95% CI 3.08 to 8.36); in men,
it was 1.85 (95% CI 1.28 to 2.69).54 With adjustment for risk
factors, these hazard ratios were reduced to 2.62 (95% CI
1.55 to 4.46) and 1.20 (95% CI 0.81 to 1.77) for women and
men, respectively. However, the positive association between
IMT and CVD risk extended over the IMT distribution. In the
Cardiovascular Health Study, a graded positive association
between IMT and the age- and sex-adjusted risk of CVD was
observed; the relative risk in the highest versus the lowest
IMT quintile was 3.87 (95% CI 2.77 to 5.51).56 Carotid IMT
development is 5 to 10 years more advanced in men than in
women, reflecting the well-known sex difference in the
development of atherosclerosis.52
Prevention trials of lipid-lowering treatments that used
IMT as a surrogate end point have shown that retardation in
the progression of IMT is accompanied by a reduction of
clinical CVD end points. These findings suggest that IMT
may be a useful measure of atherosclerotic burden.57–59
Several studies have demonstrated that in patients with
clinically manifest diabetes, carotid artery IMT is signifi-
cantly greater than in subjects of the same age who do not
have diabetes.60–64 Findings from the ARIC study suggest
that blood glucose may have a positive relationship with IMT
that extends to a nondiabetic range of glucose levels.60
Haffner et al,65 in the Insulin Resistance and Atherosclerosis
Study, compared common carotid artery and internal carotid
artery IMT in 43 subjects with type 2 diabetes with clinical
CVD, 446 subjects with type 2 diabetes without clinical
CVD, 47 nondiabetic subjects with clinical CVD, and 975
nondiabetic subjects without clinical CVD. Findings were
adjusted for age, sex, and ethnicity. Both diabetes and CVD
were associated with greater common carotid IMT. Diabetes
was also positively associated with internal carotid IMT,
whereas CVD did not show this association. Subjects with
diabetes with CVD had the greatest IMT, and nondiabetic
subjects without CVD had the lowest IMT. Subjects with
diabetes but without CVD had slightly greater IMT than
nondiabetic subjects with CVD. This study confirmed that
subjects with type 2 diabetes have a markedly increased
atherosclerotic burden even without clinical CVD. A recent
analysis from the Rotterdam Study of 374 subjects (14% with
diabetes) and 1496 controls (7% with diabetes) showed that
there was no incremental predictive value of adding IMT to a
risk function for CVD.66
Data from the ARIC study revealed a moderate association
of increased carotid IMT with incident ischemic stroke and
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CHD in people with and without diabetes. Compared with
lower IMT values, a mean carotid IMT thickness1 mm was
associated with an approximate doubling of the risk of future
cardiovascular events. The relative risks for elevated IMT
were similar for those with and without diabetes but were
somewhat higher for women than for men. After adjustment
for other CVD risk factors, the association was attenuated
slightly. Overall, it appeared that measuring IMT would add
only modestly to prediction of future CVD events in patients
with diabetes.
Conclusions
Prospective population-based studies have shown that IMT
provides incremental predictive information on the future risk
of CVD in asymptomatic subjects. These observations, how-
ever, cannot be directly extrapolated to subjects with diabe-
tes, in whom IMT has been found to be greater than in
nondiabetic subjects. There is still a paucity of research
addressing the utility of carotid IMT in predicting future
CVD risk in subjects with diabetes. Studies specifically
designed to address this question that include large enough
cohorts of subjects with diabetes are needed.
Electron Beam Tomography Measures of
Coronary Calcium
Coronary artery calcium (CAC) is a specific marker of
atherosclerosis confirmed by pathology studies.67 In clinical
coronary disease populations,68 and in various reports from
apparently asymptomatic people, electron beam tomography
(EBT) is capable of detecting CAC associated with arterial
stenosis. Although indicative of coronary atherosclerosis of
some degree, the presence of EBT-detected calcium is not
specific for obstructive coronary stenoses by angiography and
therefore cannot imply that silent ischemia is likely.
To date, few studies of EBT have been reported in subjects
with diabetes. In one study of mostly asymptomatic persons
with type 2 diabetes (mean age 62 years), CAC 0 was
associated with other diabetic complications, such as retinop-
athy, neuropathy, or nephropathy. Coronary risk factors in
this study were not predictive of abnormal coronary calcium
scores. Compared with age-matched controls, calcium scores
were generally higher (worse) in persons with diabetes than
in controls (mean of 248 in patients with diabetes versus 149
in controls), but patients in both categories were frequently
found to have scores of 0.69
EBT has also been used to study the coronary arteries in
patients with type 1 diabetes. A group from Pittsburgh70
studied 302 adults with type 1 diabetes in a long-term
diabetes cohort with a mean age of 38 years. Their main goal
was to correlate EBT findings with other evidence of CHD by
history, coronary angiography, and resting ECG. CAC scores
were compared between the 246 patients without CHD and
the 56 with CHD. In this young cohort, 61% of both men and
women without clinical CHD had no coronary artery calcium;
44% with clinical CVD had CAC 400. The CAC scores
correlated well with clinical CHD, especially in men.
In another study from England,71 199 persons with diabetes
were recruited from a population-based sampling and were
compared with 201 persons without diabetes of similar age
(30 to 55 years) and sex (50% women). Almost all subjects
were asymptomatic. In persons without diabetes, 54% of men
and 21% of women had CAC0 (age-adjusted odds ratio 4.5
for comparison of men and women). In those with diabetes,
52% of men and 47% of women had CAC (age-adjusted odds
ratio 1.2, PNS), and thus, no male/female difference was
seen here in diabetes. After adjustment for CVD risk factors,
diabetes remained associated with a 3 times higher odds ratio
of calcium in women than in men.
Conclusions
EBT detects CAC in many asymptomatic persons with
diabetes, both type 1 and 2. However, asymptomatic subjects
with diabetes often have CAC scores of 0. CAC scores in
some studies appear to correlate with the presence of clinical
CVD. Whether CAC scores predict future clinical events in
asymptomatic persons with diabetes has not been studied
adequately, and such data are needed to help define a role for
EBT in asymptomatic patients with diabetes.
Magnetic Resonance Imaging
High-resolution magnetic resonance (MR) is a noninvasive
imaging technique with excellent soft-tissue contrast that
differentiates plaque components on the basis of biophysical
and biochemical parameters (eg, chemical composition and
concentration, water content, physical state, molecular mo-
tion, and diffusion).72
Further improvement in external coils73 and the use of
contrast agents that enhance the different vessel wall compo-
nents hold great promise and may make MR suitable for
clinical use in atherosclerotic plaque diagnosis and in moni-
toring therapeutic efficacy. Future work in coronary MR
plaque imaging will certainly aim at the identification of the
different plaque components, with increasing focus on per-
sons with diabetes. This may enable identification of vulner-
able plaques before they rupture and may provide a way to
target pharmacological intervention to reduce or prevent
coronary disease. Further studies are required to explore the
potential role of MR imaging in stratifying asymptomatic
patients with diabetes according to risk.
Conclusions
The assessment of atherosclerotic plaques by imaging tech-
niques may prove valuable for the identification of vulnerable
plaques. In vivo high-resolution multicontrast MR holds
promise for noninvasively imaging vulnerable plaques and
characterizing the different components in all arteries, includ-
ing the coronary arteries. MR allows serial evaluation and
assessment of the progression and regression of atheroscle-
rosis over time. At the present time, however, information
about this technology in patients with diabetes, as well as
others, is too limited to recommend use of this modality for
clinical purposes.
Older Persons With Diabetes
The prevalence of subclinical CVD is high in older persons
(aged65 years) with diabetes, which makes any testing less
useful in stratifying risk. In a study of 1343 persons with
diabetes and 1433 patients with impaired glucose tolerance
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(mean age 73 years), a composite measure of noninvasive
markers of atherosclerosis (carotid wall thickness greater than
the 80th percentile, stenosis, low ankle-arm index, ECG or
echocardiographic abnormalities, or positive Rose question-
naire) was used. In this study, the prevalence of clinical CVD
in persons with diabetes was 40% and the prevalence of
subclinical disease was 44%, for a total of nearly 85% of
patients with either clinical or subclinical CVD compared
with 66% of persons without diabetes. The prevalence was
only slightly lower in newly diagnosed older persons with
diabetes than in persons with known diabetes. These findings
highlight that screening for subclinical disease in older adults
with diabetes would probably not be cost-effective given the
high prior probability of abnormal test result. It is important
that older persons with diabetes be considered at high risk for
CHD and that they should receive aggressive preventive
management.
Recommendation
Screening for subclinical CVD is not routinely recommended
in older persons, but the high rate of atherosclerosis in this
age groups warrants aggressive preventive management.
Special Considerations for Type 1 Diabetes
Type 1 diabetes comprises 5% to 10% of all cases of diabetes
in the United States. Owing to its earlier age of onset and
greater severity of metabolic disturbances, there are some
specific issues relating to cardiovascular risk assessment in
this group.
Both the absolute and relative risks of CVD are dramati-
cally increased in young adults with type 1 diabetes. For
subjects diagnosed in childhood, relative risks for CVD and
total mortality are often 10-fold that of the general popula-
tion.74,75 Recent 10-year incidence data suggest an absolute
annual mortality risk of 5% and CVD risk of 12% for those
with diabetes of 35 years’ duration, a group whose mean
age is only 43 years.76 Thus, the general concept that CVD
risk assessment and risk factor management should be less
vigorously applied to young adults does not appear to be
valid. Writing Group III thus held that office-based assess-
ment recommendations for adults with type 2 diabetes should
also apply to all persons with type 1 diabetes aged16 years.
This proposal is supported by the recent publication of the
predictive power of lipids and blood pressure for CVD events
in mortality in type 1 diabetes.
The use of the ABI is complicated by the high rate of
medial wall calcification in type 1 diabetes.35 Studies have
shown that an ankle brachial difference in systolic blood
pressure of 75 mm Hg has a positive predictive value of
100% for medial wall calcification.35 This measure (ankle
brachial difference of 75 mm Hg), however, is also highly
predictive of both 10-year total mortality and CVD in type 1
diabetes (relative risks of 6.7 and 3.1, respectively).77 It is
therefore recommended that when ABI is performed, either
an ABI 0.9 or an ankle brachial difference 75 mm Hg be
considered abnormal and predictive of future events. Al-
though there is increased medial wall calcification in type 1
diabetes, both published studies of EBT in type 1 diabetes
show association with CVD risk factors and CVD.70,71 Thus,
EBT has the same associations in type 1 diabetes as in the
general population, although its incremental predictive power
above CVD risk factors is not established in either
population.
In contrast to type 2 diabetes, high-density lipoprotein
cholesterol levels tend to be normal or high in type 1 diabetes
but remain predictive of events.78 The younger age at onset of
type 1 diabetes often leads to the development of advanced
microvascular complications, particularly overt nephropathy,
before the onset of CVD. This sequence is in contrast to type
2 diabetes, where the patient may die of CVD before
sufficient long-term glycemia and diabetes duration has
occurred for these other complications to develop. Overt
nephropathy and microalbuminuria are important risk factors
for CVD in type 1 diabetes, although it should be recognized
that much of the renal-associated CVD risk is linked to blood
pressure and lipid disturbances, which thus need to be
carefully monitored and treated.76
Finally, the relationship between hemoglobin A1c (or
glycemic level) and CVD is weak and inconsistent in type 1
diabetes and does not predict events well either cross-
sectionally in the United States79 or Europe79,80 or prospec-
tively in the United States.78
Cost-Effectiveness
There are no cost-effectiveness studies of alternative diagnos-
tic and risk assessment strategies for CVD in persons with
diabetes, but reasonable estimates may be possible from more
general CVD analysis if one extrapolates event rate impact
and costs. Given the number of drugs required to manage the
multiple CVD risk factors in persons with diabetes, cost-
effective assessment and management of CVD in diabetes
mellitus will require identification of strategies that are
synergistic and address more than one risk factor. Formal,
rigorous cost-effective models need to be developed that
incorporate the best data available to assess the incremental
cost-effectiveness of alternative CVD identification and man-
agement strategy (diet, exercise, and smoking cessation; cost
of test and intervention; management change; and effective-
ness of intervention on outcomes of timing).
Overall Conclusions
Mortality from CVD is greater in persons with diabetes than
in those without diabetes. Because of this greatly increased
risk, persons with diabetes should receive aggressive risk
factor modification as recommended for a secondary preven-
tion patient at high risk for CVD. Lifestyle changes—dietary
changes as well as increased physical activity—are corner-
stones of any risk management strategy, as is pharmacolog-
ical therapy, when appropriate. The value of a revasculariza-
tion strategy in asymptomatic patients has not been
established.
Traditional risk factors and a resting ECG can identify
patients with a heightened pretest probability of CVD. Office-
based risk factor evaluation is mandatory in persons with
diabetes, and aggressive risk factor modification should be
based on these results. The finding of advanced subclinical
atherosclerosis identifies a higher-risk group (true in both
persons with and those without diabetes). Exercise ECG or
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exercise SPECT appear almost equally predictive of future
events in those with and without diabetes. EBT data show that
persons with diabetes have detectable atherosclerosis at rates
higher than in persons without diabetes, consistent with the
clinical epidemiology. There are no long-term follow-up
studies yet for EBT results in persons with diabetes. How-
ever, because we already know that diabetes places patients in
a high-risk group, in general, the results of noninvasive
testing, whether negative or positive, would not change
medical management, and thus most testing for risk assess-
ment is not useful.
Currently, there are no published data to show that routine
noninvasive testing of persons with diabetes leads to better
diagnostic or therapeutic outcomes. Additional trials in this
area are mandatory to help guide decision making in this
high-risk group.
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